Every Day Counts — a lifestyle program for women with metastatic breast cancer
Official title: Every Day Counts: A lifestyle program for women metastatic breast cancer
Funded at Medical College of Wisconsin · NIH-11283938 · Data updated 2026-11-12
This program helps women living with metastatic breast cancer use exercise, strength training, and nutrition support to improve strength, body composition, blood markers, and daily quality of life.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical College of Wisconsin NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project start | February 1, 2022 |
| Project end | January 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $644,067 |
| NIH project number | 5R01CA258759-05 |
| Project ID | NIH-11283938 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are women living with metastatic breast cancer who are medically cleared to participate in an exercise and lifestyle program and can commit to scheduled visits and activities.
✕Less likely to help
Patients who are too medically fragile, have active contraindications to exercise or the intervention components, or cannot attend program activities are unlikely to benefit from participation.
What this research studies
You would join a structured lifestyle program that includes physical activity, strength training, and nutrition guidance tailored for women with metastatic breast cancer. The study team will measure your body fat and muscle mass, physical strength and activity levels, blood biomarkers, and quality of life over time. Some participants will begin the program right away while others will start later so researchers can compare results between groups. The investigators previously ran a pilot that showed participants could take part, stick with the program, and see improvements in symptoms, strength, and some biomarkers.
Why it matters
Potential benefit: If successful, the program could improve physical strength, reduce unhealthy body fat, improve biomarkers tied to prognosis, and enhance overall quality of life for women with metastatic breast cancer.
How similar studies have gone: Lifestyle programs have improved symptoms, fitness, and biomarkers in early-stage breast cancer survivors, and the study team's pilot data in metastatic patients showed promising and clinically meaningful improvements.
Where this research is happening
-
Medical College of Wisconsin
Milwaukee, United States Active
Researchers
- Principal investigator: Stolley, Melinda R — Medical College of Wisconsin
- Study coordinator: Stolley, Melinda R
Related research
Other NIH-funded projects on the same topics.
-
Understanding FGFR1-amplified breast cancer to overcome endocrine resistance
This project explores why a type of breast cancer with FGFR1 changes stops responding to hormone therapy and looks for new combination treatments that may help patients live longer.
-
Oral fulvestrant as the next standard of care for ER+ metastatic breast cancer
A new oral formulation of fulvestrant is being tested to help people with ER-positive metastatic breast cancer have a longer, better-tolerated response to treatment.
-
Fit2ThriveMB: A digital activity program to help people with metastatic breast cancer feel better and stay active
A digital, at-home physical activity program designed for people with metastatic breast cancer to improve quality of life and daily functioning.
-
Acupuncture to ease symptoms for people with metastatic breast cancer
A clinical trial will test whether weekly acupuncture for 12 weeks can reduce symptom burden for people with metastatic breast cancer who are on standard therapy.
-
Predicting end-of-life timing to guide better care for metastatic breast cancer
A clinician-facing project tests a breast cancer prognostic tool in everyday oncology care to help guide conversations and timely hospice referrals for patients nearing the end of life.
-
Combining antibody-drug conjugates with mechanism-based therapies to treat metastatic triple-negative breast cancer
A research team is testing new combination strategies that pair antibody-drug conjugates with other targeted treatments to better treat metastatic triple-negative breast cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.